Martin Dahl, PhD, of AnaptysBio discusses the findings and limitations of a study analyzing use of ANB032 in patients with atopic dermatitis (AD).
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
Martin Dahl, PhD, senior vice president of research at AnaptysBio, summarized the findings and limitations of a study that analyzed the use of ANB032, a novel nondepleting antibody that has the potential to treat many systemic inflammatory diseases, in patients with atopic dermatitis (AD).
This study's findings were presented in a poster at the 2024 American Academy of Dermatology (AAD) annual meeting.
Transcript
What were your primary findings? Did anything surprise you?
Our primary findings were confirmatory that BTLA [B and T cell lymphocyte attenuator] is expressed on the dendritic cells. It replicates a lot of literature that's out there describing the role of BTLA in dendritic cell and T-cell biology.
The results were not surprising. I think we're excited to see this induction of regulatory T cells; we'd like to see that replicated in humans. In fact, that biology, if it can be shown to happen in the skin, could contribute to the long-term durable responses.
Through the agonistic mechanism, we're turning the T cells off, which should bring the patient to a more homeostatic state and reduce their inflammatory burden. Through the expansion of regulatory T cells and the deactivation of dendritic cells, we should see a durable response that helps them maintain that tolerogenic state for a longer period, even off-drug.
Were there any study limitations? If so, what future study directions may address these challenges?
Let's see. The limitation here is that we're studying everything in vitro. Our phase 2 study in humans in atopic dermatitis will include biopsy samples from the skin, as well as tape stripping, and we're looking to confirm some of these findings in our phase 2 study.
How do environmental factors, such as allergens and irritants, interact with genetic susceptibility to exacerbate or trigger AD episodes? How can this understanding inform therapeutic strategies?
That's a great question. So, all of those factors, many of the environmental factors, the pathogen-derived factors, can be activating signals for dendritic cells; we used one of those to induce BTLA expression on the dendritic cells in our studies.
All of those things can contribute to exacerbations or chronic disease in the setting of atopic dermatitis, and that's exactly the signal we're trying to go after downstream by targeting the dendritic cells and the T cells with ANB032.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More